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Over the past quarter of a century, several scientific develop-
ments have challenged traditional concepts in ovarian cancer. 
First, it was recognized that ovarian cancer is not a homo-
geneous disease, but rather a group of diseases-each with 
different morphology and biological behavior. Approximately 
90% of ovarian cancers are carcinomas (malignant epithelial 
tumors) and, based on histopathology, immunohistochemis-
try, and molecular genetic analysis, at least five main types are 
currently distinguished: high-grade serous carcinoma (HGSC, 
70%); endometrioid carcinoma (EC,10%); clear-cell carcinoma 
(CCC,10%); mucinous carcinoma (MC, 3%); and low-grade 
serous carcinoma (LGSC, <5%) [1,2]. These tumor types (which 
account for 98% of ovarian carcinomas) can be reproducibly 
diagnosed by light microscopy and are inherently different 
diseases, as indicated by differences in epidemiologic and 
genetic risk factors; precursor lesions; patterns of spread; 
and molecular events during oncogenesis, response to 
chemotherapy, and prognosis [2,3]. Much less common are 
malignant germ cell tumors and potentially malignant sex 
cord-stromal tumors. The biomarker expression profile within 
a given histotype is consistent across stages. Ovarian cancers 
differ primarily based on histologic type.
In the era of personalized cancer medicine, reproducible 
histopathologic diagnosis of tumor cell type is a sine qua non 
for successful treatment. Different tumor histotypes respond 
differently to chemotherapy. The International Federation of 
Gynecology and Obstetrics (FIGO) Committee on Gynecologic 
Oncology unanimously agreed that histologic type should be 
designated at staging.
The finding of high-grade serous tubal intraepithelial 
car ci noma (STIC), in patients with BRCA mutation undergo-
ing risk-reducing salpingo-oophorectomy (RRSO)[4] also 
influenced the new FIGO staging. Although STIC is capable 
of metastasizing and, therefore, cannot be considered a true 
carcinoma in situ, compelling evidence for a tubal origin of 
BRCA-positive HGSC has accumulated over the past decade 
[5,6]. The relative proportion of HGSCs of ovarian and tubal 
derivation is unknown, mainly because tumor growth in 
advanced-stage cancers conceals the primary site. Even in 
cases involving BRCA mutation, evidence of a tubal origin of 
HGSCs is incomplete and a multicentric origin of these tumors 
cannot be excluded. 
The process of the proposed changes to the staging of 
ovarian, fallopian tube, and primary peritoneal cancer started 
three years ago under the leadership of the Chair of the FIGO 
Committee on Gynecologic Oncology, Professor Lynette 
Denny. The proposal was sent to all relevant gynecologic 
oncology organizations and societies worldwide. The new 
staging was reached by consensus of those participating in 
the FIGO meeting held in Rome, Italy, on October 7, 2012 and 
approved two weeks later.
The following is the consensus agreement that resulted from 
these efforts and represents new criteria for staging of these 
gynecologic cancer (Table 1).
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MAIN CHANGES
The primary site (i.e., ovary, fallopian tube, or peritoneum) 
should be designated where possible. In some cases, it might 
not be possible to delineate the primary site clearly; such 
cases should be listed as “undesignated”. The histologic type 
should be recorded.
Stage I ovarian or fallopian tube cancer is confined to the 
ovaries or the fallopian tubes and peritoneal fluid/washings. 
Tumor rupture, surface involvement by tumor cells or pres-
ence of malignant cells in the ascites or peritoneal washings 
warrants a stage of IC. It is not possible to have stage I perito-
neal cancer.
Stage II ovarian cancer comprises a small and heteroge-
neous group making up less than 10% of ovarian cancers. 
It is defined as extension or metastasis to extraovarian/
extratubal pelvic organs and may include curable tumors 
that have directly extended to adjacent organs but have 
Table 1. 2014 FIGO ovarian, fallopian tube, and peritoneal cancer staging system and corresponding TNM
Stage I. Tumor confined to ovaries or fallopian tube(s)
T1-N0-M0
IA: tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the 
ascites or peritoneal washings
T1a-N0-M0
IB: tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in the 
ascites or peritoneal washings
T1b-N0-M0
IC: tumor limited to one or both ovaries or fallopian tubes, with any of the following:
 IC1: surgical spill
T1c1-N0-M0
 IC2: capsule ruptured before surgery or tumor on ovarian or fallopian tube surface
T1c2-N0-M0
 IC3: malignant cells in the ascites or peritoneal washings
T1c3-N0-M0
Stage II. Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
T2-N0-M0
IIA: extension and/or implants on uterus and/or fallopian tubes and/or ovaries
T2a-N0-M0
IIB: extension to other pelvic intraperitoneal tissues
T2b-N0-M0
Stage III. Tumor involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes 
T1/T2-N1-M0
IIIA1: positive retroperitoneal lymph nodes only (cytologically or histologically proven):
IIIA1(i) Metastasis up to 10 mm in greatest dimension
IIIA1(ii) Metastasis more than 10 mm in greatest dimension
IIIA2: microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
T3a2-N0/N1-M0
IIIB: macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperitoneal 
lymph nodes
T3b-N0/N1-M0
IIIC: macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
T3c-N0/N1-M0
Stage IV. Distant metastasis excluding peritoneal metastases
Stage IVA: pleural effusion with positive cytology
Stage IVB: parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of 
the abdominal cavity)
Any T, any N, M1
FIGO’s staging classification for cancer of the ovary
J Gynecol Oncol Vol. 26, No. 2:87-89 www.ejgo.org 89
not yet metastasized, as well as tumors that have seeded 
the pelvic peritoneum by metastasis and, therefore, have 
a poor prognosis. The Committee felt that subdividing this 
small category further into IIB1 and IIB2 (i.e., microscopic and 
macroscopic pelvic peritoneal metastases) was not based on 
evidence/biology. All stage II disease is treated with adjuvant 
chemotherapy, so subclassification is not essential. Also, the 
old substage IIC (i.e., IIA or IIB but with tumor on surface, 
capsule ruptured, or ascites or positive peritoneal washing) 
was considered redundant and eliminated.
Most ovarian cancers are HGSCs that usually present in stage 
III, with the vast majority (84%) stage IIIC [7]. These tumors 
characteristically spread along peritoneal surfaces involving 
both pelvic and abdominal peritoneum. Less than 10% of 
ovarian carcinomas extend beyond the pelvis with exclusively 
retroperitoneal lymph node involvement. Evidence in the 
literature indicates that these cases have a better prognosis 
than that of tumors with abdominal peritoneal involvement 
[8-14]. The new staging includes a revision of stage III patients 
and assignment to stage IIIA1 based on spread to the retro-
peritoneal lymph nodes without intraperitoneal dissemina-
tion. Stage IIIA1 is further subdivided into IIIA1(i) (metastasis 
≤10 mm in greatest dimension) and IIIA1(ii) (metastasis >10 
mm in greatest dimension), even if there are no retrospective 
data supporting quantification of the size of metastasis in 
IIIA1. Involvement of retroperitoneal lymph nodes must be 
proven cytologically or histologically. 
Stage IV is defined as distant metastasis and includes 
patients with parenchymal liver/splenic metastases and 
extra-abdominal metastases; 12% to 21% of patients present 
with stage IV disease [7]. Extension of tumor from omentum 
to spleen or liver (stage IIIC) should be differentiated from 
isolated parenchymal metastases (stage IVB).
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